Wang Yue, Kong Jingchun, Zhang Xiaodong, Liu Yan, Huang Zeyu, Yuan Lu, Zhang Ying, Cao Jianming, Chen Lijiang, Liu Yong, Zhou Tieli
Department of Clinical Laboratory, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Department of Medical Lab Science, School of Laboratory Medicine and Life Science, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Front Microbiol. 2022 Sep 29;13:1020652. doi: 10.3389/fmicb.2022.1020652. eCollection 2022.
The global emergence and spread of multi-drug resistant (MDR) strains is becoming increasingly worrisome due to the overuse of broad-spectrum antibiotics. Colistin, the last resort for treating MDR strains infections, has once again returned to the clinician's choice. However, with the widespread use of colistin, colistin-resistant gram-negative bacteria (GNB) have subsequently emerged, including colistin-resistant (COL-R PA). Therefore, available solutions are urgently needed to respond to this situation. Here, we inspiringly found that the combination of plumbagin and colistin had an efficiently inhibitory effect for colistin-resistant through checkerboard assay and time-kill assay. The combinatorial inhibition of biofilm formation was clearly demonstrated by crystal violet staining and scanning electron microscopy (SEM), and this combination can not only inhibited biofilm formation but also eradicated the mature biofilm. Erythrocytes hemolysis test showed that plumbagin has negligible hemolysis ability. In addition, the increased survival rate of () larva confirmed this combination as same as effective . As for the mechanism of this combination, propidium iodide (PI) staining showed colistin combined with plumbagin could significantly change the membrane permeability, thus exerting synergistic antibacterial activity. In conclusion, the combination of plumbagin and colistin shows a prominently synergistic antibacterial effect and , providing a promising option for the therapy of COL-R PA infection.
由于广谱抗生素的过度使用,多重耐药(MDR)菌株在全球的出现和传播日益令人担忧。黏菌素作为治疗MDR菌株感染的最后手段,再次成为临床医生的选择。然而,随着黏菌素的广泛使用,耐黏菌素革兰氏阴性菌(GNB)随后出现,包括耐黏菌素(COL-R PA)。因此,迫切需要有效的解决方案来应对这种情况。在这里,我们通过棋盘法和时间杀菌试验令人鼓舞地发现,白花丹素和黏菌素的组合对耐黏菌素具有高效抑制作用。结晶紫染色和扫描电子显微镜(SEM)清楚地证明了对生物膜形成的联合抑制作用,并且这种组合不仅可以抑制生物膜形成,还可以根除成熟的生物膜。红细胞溶血试验表明白花丹素的溶血能力可忽略不计。此外,秀丽隐杆线虫(Caenorhabditis elegans)幼虫存活率的提高证实了这种组合与有效的[未明确内容]相同。至于这种组合的作用机制,碘化丙啶(PI)染色显示黏菌素与白花丹素结合可显著改变膜通透性,从而发挥协同抗菌活性。总之,白花丹素和黏菌素的组合显示出显著的协同抗菌作用,为COL-R PA感染的治疗提供了一个有前景的选择。